

REMARKS

The application contains claims 9-12.

The rejection of Claims 9, 11, and 12 under 35 USC 102(e) as being anticipated by Braje et al., US Patent No. 2005/013,186 has been maintained by the Examiner. Claim 9 has been amended such that R² does not represent hydrogen. Therefore, this rejection of the claims is now moot.


The Examiner has indicated that Claim 10 is objected to but would be allowable if rewritten in independent format. Applicants have rewritten Claim 10 in independent format per the Examiner's suggestion. Therefore, Claim 10 should now be allowable.

It is respectfully submitted that the present application is in condition for allowance. The Examiner is invited to contact the undersigned to discuss this case if desired.

Enclosed is a Letter which lists co-pending applications, as well as an Supplemental Information Disclosure Statement with PTO1449 and the accompanying references.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to Deposit Account No. 07-1392.

Respectfully submitted,


Bonnie L. Deppenbrock
Attorney for Applicant
Registration No. 28,209

Date: May 7, 2009
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-1577
Facsimile: 919-483-7988